Summary

Gastrointestinal disease is a very common and frequently occurring disease, with a wide range of types and a total incidence of about 20% of the population. The cause of gastrointestinal disease is the imbalance between the protective mechanism and the injury mechanism of the human body. While traditional medicine kills harmful bacteria in the stomach, it also kills the beneficial bacteria necessary for the stomach. Although the symptoms are alleviated and inflammation is eliminated, the reduction of beneficial bacteria reduces the gastrointestinal immunity. Once the drug is stopped, it is easy to re-infect. There are many reasons for stomach problems, including genetics, environment, diet, drugs, bacterial infections, etc., as well as smoking and excessive alcohol consumption. This collection of entries aims to collect various items related to the topic of gastrointestinal diseases, such as clinical care, case cases, disease research, etc., to help people increase their knowledge and understanding of this common disease

Expand All
Entries
Topic Review
Sulfate-Reducing Bacteria
Sulfate-reducing bacteria (SRB) are a group of anaerobic microorganisms that can be present in the environment and gastrointestinal tract as a part of the intestinal microbiome and can be involved in inflammatory bowel diseases (IBDs), including ulcerative colitis in the human and animals.
  • 2.2K
  • 07 Feb 2021
Topic Review
Gut Microbiota Alteration and HCV
The gut–liver-axis is a bidirectional coordination between the gut, including microbial residents, the gut microbiota, from one side and the liver on the other side. Any disturbance in this crosstalk may lead to a disease status that impacts the functionality of both the gut and the liver. A major cause of liver disorders is hepatitis C virus (HCV) infection that has been illustrated to be associated with gut microbiota dysbiosis at different stages of the disease progression. This dysbiosis may start a cycle of inflammation and metabolic disturbance that impacts the gut and liver health and contributes to the disease progression. This review discusses the latest literature addressing this interplay between the gut microbiota and the liver in HCV infection from both directions. Additionally, we highlight the contribution of gut microbiota to the metabolism of antivirals used in HCV treatment regimens and the impact of these medications on the microbiota composition.
  • 621
  • 09 Apr 2021
Topic Review
Gastroschisis
The International Clearinghouse for Birth Defects Surveillance and Research defines gastroschisis as "a congenital malformation characterized by visceral herniation usually through a right side abdominal wall defect to an intact umbilical cord and not covered by a membrane". Approximately 10% of infants with gastroschisis have intestinal stenosis or atresia resulting from vascular insufficiency due to a volvulus or compression of vascular pedicle by a narrowing abdominal ring.
  • 995
  • 30 Jan 2021
Topic Review
Fibroblast Subsets in Colorectal cancer
CAFs are defined as fibroblasts surrounding malignant tumor cells and are the most abundant cell type in the tumor microenvironment of colorectal cancer (CRC). CAFs consist of various functionally heterogeneous subsets which can promote or restrain cancer progression. Although most previous research has focused on the biology of epithelial cells, accumulating evidence shows that certain CAF subsets can also importantly contribute to tumor initiation and progression, thereby possibly providing avenues for improvement of clinical care for CRC patients. However, attention needs to be paid to comprehensive characterization and reporting of the subsets being investigated in CAF studies to enable more precise identification and targeting of “unfavorable” CAFs in advanced CRC.
  • 543
  • 28 Jan 2021
Topic Review
Vitamin D, microbiome, and IBD
Inflammatory bowel disease (IBD) is a chronic inflammation of the gastrointestinal tract (GIT), including Crohn’s disease (CD) and ulcerative colitis (UC), which differ in the location and lesion extensions. Both diseases are associated with microbiota dysbiosis, with a reduced population of butyrate-producing species, abnormal inflammatory response, and micronutrient deficiency (e.g., vitamin D hypovitaminosis). Vitamin D (VitD) is involved in immune cell differentiation, gut microbiota modulation, gene transcription, and barrier integrity. Vitamin D receptor (VDR) regulates the biological actions of the active VitD (1α,25-dihydroxyvitamin D3), and is involved in the genetic, environmental, immune, and microbial aspects of IBD. VitD deficiency is correlated with disease activity and its administration targeting a concentration of 30 ng/mL may have the potential to reduce disease activity. Moreover, VDR regulates functions of T cells and Paneth cells and modulates release of antimicrobial peptides in gut microbiota-host interactions. Meanwhile, beneficial microbial metabolites, e.g., butyrate, upregulate the VDR signaling.
  • 755
  • 31 Jan 2021
Topic Review
Helicobacter pylori Infections
The objective of this entry is twofold. First, author perform a systematic review ofthe economic evaluation studies applied to assess the efficiency of diagnostic testing for the H. pylori infection. Author intend to summarize the methods applied to these economic evaluations and to highlight the main characteristics of these studies. The second objectiveis to learn from the literature review how the AMR issue is incorporated in economic evaluation of diagnostic testing.
  • 519
  • 05 Feb 2021
Topic Review
Deadly Helminthiasis
Helminthiasis is an expensive management problem in sheep and goat industry, because the gastrointestinal parasites develop resistance against all anthelmintic chemical products which are discovered and produced by the pharmaceutical industry. The use of natural tannin containing forages such as Sericea Lespedeza is highly promising. Helminthiasis is the invasion of internal parasites into the GI tract of domestic animals, even in humans, causing serious deadly consequences. Sheep and goats are more seriously afflicted than other farm animals. Helminthiasis results in high mortality rate, and poor growth rates, low reproductive performances and low quality products produced from infected animals, which increase high production costs. Anthelmintic drug has been used as the most common control method against gastrointestinal nematodes (GIN) infection. Overuse and misuse of these drugs caused significant GIN resistance against the drugs, especially in sheep and goat production.  
  • 597
  • 18 Jan 2021
Topic Review
Gastrointestinal-Bleeding between NOACs and VKAs
Non-vitamin K antagonist oral anticoagulants (NOACs) are more commonly used to prevent atrial fibrillation (AF) patients from thromboembolic events than vitamin K antagonists (VKAs). However, the gastrointestinal bleeding (GIB) risk in the Asian AF patients associated with NOACs in comparison with VKAs remained unaddressed.
  • 544
  • 15 Jan 2021
Topic Review
Gut Microbiota in the Elderly
Gut microbiota is involved in the maintenance of physiological homeostasis, thus the alteration of its composition and functionality, called dysbiosis, has been associated with many pathologies, and could also be linked with the progressive degenerative process in aging. Specific gut microbiota taxa could be associated to the development of inflammation underlying aging, but also it has been identified some beneficial profiles related to a healthy status in the elderly. Thus, gut microbiota emerges as a therapeutic target with a double impact in the elderly, counteracting both aging itself and associated diseases. 
  • 573
  • 12 Jan 2021
Topic Review
Her-2 in Gastrointestinal Tumours
Gastrointestinal (GI) tumors account for a quarter of all the cancer burden and a third of the global cancer-related mortality. Among them, some cancers retain a dismal prognosis; therefore, newer and innovative therapies are urgently needed in priority disease areas of high-unmet medical need. In this context, HER2 could be a relevant prognostic and predictive biomarker acting as a target for specific drugs. However, if the role of HER2 has been object of investigation for several years in gastric cancer, it is not well established in other GI malignancies. The aim of this narrative review was to portray the current landscape of the potential role of HER2 as a predictive biomarker for GI tumors beyond gastric cancer. In colon cancer, the benefit from anti-HER2 therapies is less clear than in gastric neoplasms for the lack of controlled studies. Pancreatic, biliary tract adenocarcinomas and hepatocarcinoma may derive a less clear clinical benefit by using anti-HER2 agents in HER2 positive tumors. Overall, the results are promising and seem to suggest that the integration of multiple modalities of therapies can optimize the cancer care. However, further prospective trials are needed to validate the use of personalized targeted therapies in this field.
  • 495
  • 11 Jan 2021
  • Page
  • of
  • 39

Featured Entry Collections

>>